Projects & Networking Opportunities

A specialized medical dermatology company required a solution to effectively treat inflammatory dermatoses and protect compromised skin barriers from opportunistic bacterial infections. To address this, the team engineered a patented topical formulation utilizing antimicrobial micro-elements and barrier-repairing compounds, produced under strict Good Manufacturing Practice (GMP) standards. This initiative successfully delivered a clinically proven medicinal skincare line to international pharmaceutical licensees, significantly improving targeted treatment options for chronic skin conditions.

The animal health sector requires cost-effective, scalable immunotherapies to combat high-impact infectious diseases in livestock and counteract post-surgical immunosuppression in companion animals. In response, a biotechnology developer engineered a cell-free, synthetic platform utilizing surface-functionalized silica nanoparticles as a dual-action carrier and innate immune stimulator. The deliverable provides an adaptable, low-cost prophylactic that significantly improves survival outcomes and immune activation over established commercial benchmarks across mass-market veterinary indications.

A clinical-stage biopharmaceutical venture navigating the complex commercialization path for an aerosolized protease inhibitor targeting acute viral respiratory infections. To resolve this, project leadership synthesized patented inhalation formulation data, historical clinical efficacy findings, and standardized regulatory documentation into a consolidated asset portfolio. This initiative established comprehensive transaction deliverables and an active divestment roadmap to execute a full corporate sale or international licensing agreement.

A specialty bio-ingredient developer faced the challenge of entering a competitive overseas cosmetics market while mitigating high international travel overhead and standardizing flexible B2B commercial terms. The team implemented a targeted portfolio strategy featuring proprietary green-chemistry formulations supported by local in-territory representation. This initiative aimed to secure commercial agreements with tier-one personal care manufacturers.

B2B Platform for Business Development in the Pharmaceutical Industry.

In-Licensing Pharmaceutical Products for the German market (Gynaecology, Proctology, Gastroenterology, Children Vitamines).

A newly formed biopharmaceutical venture, founded by former leadership from a specialized European pharmaceutical company, is advancing therapeutic programs targeting central serotonin deficiency across chronic pain and neuro-inflammatory indications. The platform leverages derisked, known active compounds backed by existing human clinical efficacy data, with concurrent plans to integrate a companion diagnostic for targeted patient stratification. The team is currently raising a low-single-digit million-euro seed round to complete initial formulation milestones and conduct formal scientific advice procedures with regional regulatory authorities.

An emerging biotechnology firm required strategic operational and financial support to close an eight-figure growth round and scale the global commercialization of its certified in vitro diagnostic platform. The project team deployed targeted investor outreach, structured licensing and distribution frameworks, and identified strategic co-development opportunities with multinational life sciences and diagnostics corporations. The primary deliverable is accelerating market penetration across key international territories while expanding the platform’s validated clinical applications from targeted organ transplant management into broader autoimmune indications.

A clinical-stage medical diagnostics venture required substantial capital and industrial support to advance an integrated photonics diagnostic platform from preclinical validation through stringent regulatory clearance and commercial manufacturing. To resolve this, a strategic partnering and syndicate-building framework was deployed to mobilize specialized health-tech investors and commercial partners around the venture's optical biosensor hardware and consumable microfluidic cartridges. The initiative is structured to secure a multi-million-euro funding round, de-risk regulatory certification for a flagship antibiotic allergy test, and establish industrial licensing and co-development pipelines to scale the diagnostic platform into immunology and infectious disease applications.

Organizations frequently struggle with regulatory compliance and life-safety readiness due to unmaintained emergency medical hardware and a lack of trained response personnel in high-traffic facilities. To solve this, an equipment-as-a-service framework converts standalone automated external defibrillators into a fully managed subscription model integrating hardware installation, continuous monitoring, preventive maintenance, and recurring certified staff training. Supported by a mid-five-figure non-dilutive debt facility collateralized by multi-year commercial service contracts, the project aims to deploy dozens of turnkey emergency response hubs to significantly increase cardiac arrest survival rates while expanding predictable recurring revenue.

Immediately available BD & Launch Management Professional (Pharma)

MA available for Germany: TRIAMCINOLONE ACETONIDE (55µg/dose - Nasal spray, 120 doses) Generic to NASACORT® (SANOFI)